NEW HAVEN, Conn.–(BUSINESS WIRE)–Veradermics, Incorporated (“Veradermics”), (NYSE: MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the pricing of its upsized initial public offering of 15,077,647 shares of its common stock at an initial public offering price of $17.00 per share. All of the … [Read more…]

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its fourth quarter and full year 2025 financial results before the opening of the financial markets on Tuesday, February 24, 2026. Management will host a teleconference … [Read more…]

Q3’26 Revenue Increased 26% to $83.9 Million Q3’26 Service Revenue Increased 29% to $53.7 Million Q3’26 Distribution Revenue Grew 20% to $30.2 Million on Increased Demand for Rentals Q3 ’26 Gross Margin Expanded 60 Basis Points to 30.1% Management Reaffirms Fiscal 2026 Service Revenue Expectations Management to Host Conference Call Today at 4:30 p.m. Eastern … [Read more…]

FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–In a notice published earlier today, the Florida Department of Health (DOH) retreated on its decision to make cuts to the State’s AIDS drug program, which provides life-saving medications and health insurance support to over 30,000 Floridians living with HIV/AIDS. Alleging that an undocumented $120 million budget shortfall necessitated the cuts, the … [Read more…]

BIRMINGHAM, Ala.–(BUSINESS WIRE)–#biotech–Southern Research and London-based Pathogenus Consulting have signed a three-year partnership that will allow both organizations to capitalize on growing research opportunities around the world. “We’ve seen clear momentum in our work with partners outside the United States, especially with Japan and European pharmaceutical companies, and the opportunity to broaden that footprint is … [Read more…]

Seasoned drug discovery leader will join Valo to further advance human-centric, AI-enabled drug discovery LEXINGTON, Mass.–(BUSINESS WIRE)–#DrugDiscovery—Valo Health, Inc. (“Valo”), a company pioneering the use of human data and AI to accelerate drug discovery and development, today announced the appointment of Karin Conde-Knape, Ph.D., as Chief Scientific Officer (CSO). Dr. Conde-Knape brings more than two … [Read more…]

PARIS & PALO ALTO, Calif.–(BUSINESS WIRE)–LBO France, a multi-specialist investment platform and pioneer in private equity, announced today the signing of a definitive agreement with Vivo Capital, a leading global investment firm focused exclusively on healthcare and life sciences, for the sale of Dutscher Group (‘Dutscher’ or ‘the Group’), the European leader in consumables and … [Read more…]

WASHINGTON–(BUSINESS WIRE)–By virtue of its exclusive contract to manage the 340B Drug Pricing Program since 2004, Apexus has become a government-sanctioned entity fraught with self-dealing interests in the 340B marketplace. AIDS Healthcare Foundation (AHF) welcomes Senator Bill Cassidy’s (R-LA) inquiry into Apexus. The prime vendor is a wolf in sheep’s clothing, leveraging its former nonprofit … [Read more…]

An All-New Docuseries from Executive Producers Jeannie Mai, Alyssa Milano, and Award-Winning Filmmakers Sadhvi Siddhali Shree and Sadhvi Anubhuti NEW YORK–(BUSINESS WIRE)–Tellory sponsored a luncheon in celebration of the premiere of Balance: A Perimenopause Journey, a new docuseries produced by Jeannie Mai and Alyssa Milano that explores the often misunderstood and under-discussed realities of perimenopause. … [Read more…]

CHICAGO–(BUSINESS WIRE)–Veradigm® (OTCMKTS: MDRX), a leading provider of clinical and revenue cycle solutions for independent practices, today announced that its Board of Directors (the “Board”) has approved an amendment to extend the Company’s existing Stockholder Rights Plan to December 31, 2026 (the “Rights Plan”). The Board’s decision to extend the Rights Plan is based on … [Read more…]